Evonik Industries (EVK) CMD 2025 summary

Strategic transformation and vision

• Introduced a new group structure with two segments: Custom Solutions (innovation-driven, niche markets) and Advanced Technologies (efficiency-driven, operational excellence), each with distinct management and financial KPIs.

• Launched a new vision positioning as "Industry's Superforce," emphasizing a leading portfolio, sustainable innovation, regional balance, and team excellence.

• Aims for a balanced global sales footprint: one-third of sales in Americas, Asia, and Europe/EMEA, with ongoing investments in Asia and increased local-for-local production.

• Portfolio strategy includes divesting the C4 business, German infrastructure sites, and Performance Intermediates, with ongoing fine-tuning and a “fix-it-or-sell-it” approach.

• Cultural focus on team excellence, accountability, openness, respect, and performance to support transformation and sustainable success.

Financial targets and capital allocation

• Targets €1 billion additional EBITDA by 2027 (base year 2023), split equally between growth and optimization, with €400 million already achieved in 2024.

• ROCE set as the top KPI, aiming for around 11% by 2027, with all management incentives aligned to this goal and >40% cash conversion rate.

• Free cash flow generation expected to reach €5.5 billion over three years (2025–2027), with sustainable CapEx of €850–900 million per year, split 50/50 between growth and maintenance.

• Capital allocation priorities: 50% to CapEx, 30% to dividends, 20% to debt reduction; no significant M&A until 2027, but share buybacks and targeted M&A possible post-divestments.

• Most restructuring costs already provisioned; no major new provisions expected.

Growth and optimization initiatives

• €500 million EBITDA growth from investments in PA12 (Germany), Silica (US), Alkoxides (Singapore), Metal Oxides (Japan), biosurfactants (Slovakia), and membranes (Austria).

• €500 million net savings from the "Evonik Tailor Made" reorganization, business optimization (Animal Nutrition, Health Care, Silica/Silanes, Polymers, Crosslinkers), and procurement optimization.

• "Evonik Tailor Made" aims to reduce up to 2,000 employees by 2026, cut hierarchy levels, and achieve -80% personnel and -20% non-personnel cost reductions.

• Innovation Growth Areas expected to generate €1.5 billion additional sales by 2032 at >20% EBITDA margin, focusing on biosolutions, circular economy, and energy transition.

• Process innovation (Next Generation Technologies) to drive cost leadership and GHG reduction, with projects like waste heat upcycling and process redesign.